Brought to you by 
PPD signs new in-license deal with Lilly for dapoxetine
21 Jul 2004
Executive Summary
Pharmaceutical Product Development (discovery and development services and compound partnering) will acquire from Lilly the patents for dapoxetine for development in the genitourinary field. PPD agrees to pay Lilly $65mm in cash up front, plus a royalty on net sales in excess of a set threshold (reported in industry news as 5% on sales over $800mm a year).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PPD signs new in-license deal with Lilly for dapoxetine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice